Hartford Financial Management Inc. boosted its position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 65.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,300 shares of the company’s stock after buying an additional 8,000 shares during the quarter. Hartford Financial Management Inc. owned approximately 0.10% of Fennec Pharmaceuticals worth $81,000 as of its most recent filing with the SEC.
Separately, Geode Capital Management LLC boosted its stake in shares of Fennec Pharmaceuticals by 16.0% during the 4th quarter. Geode Capital Management LLC now owns 39,489 shares of the company’s stock worth $251,000 after acquiring an additional 5,441 shares during the period. 48.39% of the stock is currently owned by institutional investors.
Shares of FENC opened at $4.59 on Wednesday. The firm has a market cap of $90.00 million, a PE ratio of -9.18 and a beta of -0.17. The stock has a 50-day moving average price of $4.17. Fennec Pharmaceuticals Inc has a 12-month low of $3.26 and a 12-month high of $10.55.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Article: Preferred Stock
Want to see what other hedge funds are holding FENC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fennec Pharmaceuticals Inc (NASDAQ:FENC).
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.